Search Results | Diabetes | American Diabetes Association

1-7 of 7

Sort by

Sort Order Select

Meeting Abstracts

833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial

FRANCESCO GIORGINO, JULIO ROSENSTOCK, ROBERT RITZEL, OGUZHAN DEYNELI, AGUSTINA ALVAREZ, ELISABETH SOUHAMI, LYDIE MELAS-MELT, RORY J. MCCRIMMON

Diabetes 2022;71(Supplement_1):833-P

DOI: https://doi.org/10.2337/db22-833-P

Published: 01 June 2022

View article

Meeting Abstracts

Self- vs. Physician-Led Titration of Insulin Glargine 300 U/mL (Gla-300)—Improved or Comparable Efficacy at Week 24 without Increased Risk of Hypoglycemia, Irrespective of Age (<65 or =65 Years)—TAKE CONTROL

KRZYSZTOF STROJEK, GREGORY BIGOT, MIREILLE BONNEMAIRE, ELIAS DELGADO, VIERA DONICOVA, MILAN KVAPIL, NIKOLAOS PAPANAS, LUIZA POPESCU, ROBERT RITZEL, BERND SCHULTES, LEA DUVNJAK

Diabetes 2018;67(Supplement_1):303-OR

DOI: https://doi.org/10.2337/db18-303-OR

Published: 01 July 2018

View article

Meeting Abstracts

Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study

ALICE Y.Y. CHENG, JULIO ROSENSTOCK, ROBERT RITZEL, ZSOLT BOSNYAK, CHRISTINE DEVISME, PETER STELLA, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, GEREMIA B. BOLLI

Diabetes 2018;67(Supplement_1):301-OR

DOI: https://doi.org/10.2337/db18-301-OR

Published: 01 July 2018

View article

Meeting Abstracts

Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study

RONAN ROUSSEL, JULIO ROSENSTOCK, JEREMY PETTUS, ROBERT RITZEL, ALICE CHENG, ZSOLT BOSNYAK, CHRISTINE DEVISME, ANNA M. CALI, XIANGLING WANG, GEREMIA B. BOLLI

Diabetes 2018;67(Supplement_1):1029-P

DOI: https://doi.org/10.2337/db18-1029-P

Published: 01 July 2018

View article

Meeting Abstracts

Similar Variability of Fasting and 24-h Self-Measured Plasma Glucose (SMPG) with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM—The Randomized BRIGHT Trial

ALICE Y.Y. CHENG, ROBERT RITZEL, ZSOLT BOSNYAK, EMMANUELLE BOELLE-LE CORFEC, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, GEREMIA B. BOLLI

Diabetes 2018;67(Supplement_1):1036-P

DOI: https://doi.org/10.2337/db18-1036-P

Published: 01 July 2018

View article

Journal Articles

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Alexandra E. Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A. Rizza, Peter C. Butler

Diabetes 2003;52(1):102–110

DOI: https://doi.org/10.2337/diabetes.52.1.102

Published: 01 January 2003

View article

Journal Articles

Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance

Robert Ritzel, Miriam Schulte, Niels Pørksen, Markus S. Nauck, Jens J. Holst, Claus Juhl, Winfried März, Ole Schmitz, Wolff H. Schmiegel, Michael A. Nauck

Diabetes 2001;50(4):776–784

DOI: https://doi.org/10.2337/diabetes.50.4.776

Published: 01 April 2001

View article

NARROW

833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial

Self- vs. Physician-Led Titration of Insulin Glargine 300 U/mL (Gla-300)—Improved or Comparable Efficacy at Week 24 without Increased Risk of Hypoglycemia, Irrespective of Age (<65 or =65 Years)—TAKE CONTROL

Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study

Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study

Similar Variability of Fasting and 24-h Self-Measured Plasma Glucose (SMPG) with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM—The Randomized BRIGHT Trial

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial

Self- vs. Physician-Led Titration of Insulin Glargine 300 U/mL (Gla-300)—Improved or Comparable Efficacy at Week 24 without Increased Risk of Hypoglycemia, Irrespective of Age (<65 or =65 Years)—TAKE CONTROL

Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study

Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study

Similar Variability of Fasting and 24-h Self-Measured Plasma Glucose (SMPG) with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM—The Randomized BRIGHT Trial

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only